Phase 4 N=78 Efficacy of Azithromycin in Treatment of Bronchiectasis
Bronchiectasis
Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=38 Effects of Inspiratory Muscle Training in Patients With Bronchiectasis
Bronchiectasis
Primary: Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) at 8 Weeks — 60; 71; 84; 69 cmH2O — p=0.005
Phase 4 N=196 Prevention of OM-85 on Bronchiectasis Exacerbation
Bronchiectasis With Acute Exacerbation
Primary: Bronchiectasis Exacerbation — 0.98; 0.75 proportion of acute exacerbations
N/A N=90,089 Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis
Bronchiectasis
Primary: Nontuberculous Mycobacterial (NTM) Disease — 188; 32 Events — p=0.19
Phase 2 N=124 Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29). — -2.94; -0.32 log10 of CFU per gram sputum — p=< 0.001
Phase 3 N=266 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 7.4; 5.7 units on a scale — p=0.68
Phase 3 N=274 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Bronchiectasis
Primary: Change in QOL-B Respiratory Symptoms Score at Day 28 — 8.2; 3.2 units on a scale — p=0.011
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
N/A N=544 Assessment of an Exhaled Breath Test to Detect Bronchiectasis
Bronchiectasis
Primary: The Ability of the Breath Test Model to Distinguish Bronchiectasis From Healthy People — 65; 67; 23 Participants — p=<0.05
Phase 2 N=52 Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
Bronchiectasis · Lung Disease · Respiratory Diseases
Primary: Ratio of Absolute Neutrophil Cell Count in Sputum at End of Treatment Compared to Baseline — 0.31; 1.00 ratio — p=0.004
Phase 3 N=1,721 A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
Primary: Annualized Rate of Pulmonary Exacerbations (PEs) — 1.015; 1.036; 1.286 exacerbation per participant-year — p==0.0019
Phase 3 N=416 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks — 336; NA; 186 Days — p=0.0650
Phase 2 N=256 Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
Primary: Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period — NA; NA; 189.0 days — p== 0.014
N/A N=161 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis
Non-Cystic Fibrosis Bronchiectasis
Primary: Median Number of Exacerbations — 1; 2 exacerbations
Phase 2 N=131 Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis
Bronchiectasis
Primary: Reliability of the Respiratory Domain of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) — 0.80 Intraclass Correlation Coefficient
Phase 3 N=521 Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo — NA; NA Days — p=0.0511
Phase 2 N=38 A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
Bronchiectasis
Primary: Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline — 1.08; 1.01 ratio
Phase 4 N=152 Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
Primary: Bacterial Clearance Rate of Sputum — 38; 16 Participants
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 2 N=64 Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
Bronchiectasis
Primary: Number of Participants Reporting Treatment-emergent AEs (TEAEs) up to End of Treatment — 2; 3; 2; 3 Participants
Phase 4 N=14 Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
Cystic Fibrosis
Primary: Average Rate of Mucociliary Clearance (MCC) Over 60 Minutes — 14.8 percent cleared over 60 minutes — p=0.04
Phase 2 N=48 Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
Non-cystic Fibrosis Bronchiectasis · Pseudomonas Aeruginosa · Lung Infection
Primary: P. Aeruginosa Recovery in Sputum Following Multiple Doses of AP-PA02 Administered by Inhalation — -0.5; -0.1; -0.4; 1.0 colony forming units log10
N/A N=197 Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
Infections, Streptococcal
Primary: Number of Subjects With Bacterial Aetiology, Assessed by Culture Growth, From Bronchoalveolar Lavage (BAL) Fluid Samples — 141; 49; 1; 58 Participants
Phase 4 N=12 The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis
COPD · Chronic Bronchitis · Emphysema
Primary: Difference in Mucociliary Clearance (MCC) Between Visit 1A and Visit 2A — -1.50; -0.70 percentage difference of MCC
Phase 2 N=48 Effect of BIBW 2948 BS in COPD
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
Phase 2 N=107 Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Non-cystic Fibrosis Bronchiectasis
Primary: Change From Baseline to Day 29 in Pseudomonas Aeruginosa (P. Aeruginosa) Density in Sputum (log10 CFUs) — 6.80; 7.67; 6.10; 6.98 log10 CFUs
Phase 4 N=83 Azithromycin in Bronchiolitis Obliterans Syndrome
Bronchiolitis Obliterans Syndrome · Graft Rejection · Lymphocytic Bronchiolitis
Primary: Prevalence of Bronchiolitis Obliterans Syndrome (BOS) — 5; 19 participants
Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
Phase 3 N=18 Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Chronic Obstructive Pulmonary Diseases · Chronic Airways Limitation · Bronchitis
Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage